Andrew H Wei
Overview
Explore the profile of Andrew H Wei including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
150
Citations
10980
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Appelbaum J, Wei A, Mandrekar S, Tiong I, Chua C, Teh T, et al.
Leukemia
. 2024 Jan;
38(2):389-392.
PMID: 38263433
No abstract available.
22.
Rajakumaraswamy N, Gandhi M, Wei A, Sallman D, Daver N, Mo S, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Jan;
24(4):260-268.e2.
PMID: 38216397
Introduction: Azacitidine (AZA) is an approved frontline therapy for higher-risk myelodysplastic syndromes (HR-MDS); however, poor survival denotes unmet needs to increase depth/duration of response (DOR). Methods: This retrospective study with...
23.
Jimenez-Chillon C, Othman J, Taussig D, Jimenez-Vicente C, Martinez-Roca A, Tiong I, et al.
Blood Adv
. 2023 Dec;
8(2):343-352.
PMID: 38039513
Molecular failure in NPM1-mutated acute myeloid leukemia (AML) inevitably progresses to frank relapse if untreated. Recently published small case series show that venetoclax combined with low-dose cytarabine or azacitidine can...
24.
Brunner A, Esteve J, Porkka K, Knapper S, Traer E, Scholl S, et al.
Am J Hematol
. 2023 Nov;
99(2):E32-E36.
PMID: 37994196
The safety and efficacy of sabatolimab, a novel immunotherapy targeting T-cell immunoglobulin domain and mucin domain-3 (TIM-3), was assessed in combination with hypomethylating agents (HMAs) in patients with HMA-naive revised...
25.
Ravandi F, Dohner H, Wei A, Montesinos P, Pfeilstocker M, Papayannidis C, et al.
Br J Haematol
. 2023 Nov;
204(3):877-886.
PMID: 37952982
In the phase 3 QUAZAR AML-001 trial (NCT01757535) of patients with acute myeloid leukaemia (AML) in remission following intensive chemotherapy (IC) and ineligible for haematopoietic stem cell transplant (HSCT), oral...
26.
Pabst T, Papayannidis C, Demirkan F, Doronin V, Fogliatto L, Guttke C, et al.
Lancet Haematol
. 2023 Nov;
10(11):e902-e912.
PMID: 37914483
Background: Cusatuzumab, a high-affinity anti-CD70 antibody, has shown preliminary activity as a treatment for acute myeloid leukaemia when combined with azacitidine. We aimed to determine the optimum dose for future...
27.
Stahl M, Bewersdorf J, Xie Z, Della Porta M, Komrokji R, Xu M, et al.
Blood Rev
. 2023 Sep;
62:101128.
PMID: 37704469
The guidelines for classification, prognostication, and response assessment of myelodysplastic syndromes/neoplasms (MDS) have all recently been updated. In this report on behalf of the International Consortium for MDS (icMDS) we...
28.
Ravandi F, Cloos J, Buccisano F, Dillon R, Dohner K, Freeman S, et al.
Am J Hematol
. 2023 Sep;
98(12):1847-1855.
PMID: 37671649
With the availability of effective targeted agents, significant changes have occurred in the management of patients with acute myeloid leukemia (AML) over the past several years, particularly for those considered...
29.
Fleming S, Cheng-Hong Tsai X, Morris R, Hou H, Wei A
Blood
. 2023 Aug;
142(23):2029-2033.
PMID: 37647854
This study reports the following: (1) frequency of TP53 comutation within each component of the European LeukemiaNet 2022 acute myeloid leukemia risk classification, (2) relevance of TP53 mutated variant allelic...
30.
Loo S, Roberts A, Anstee N, Kennedy G, He S, Schwarer A, et al.
Blood
. 2023 Aug;
142(23):1960-1971.
PMID: 37647654
Sorafenib maintenance improves outcomes after hematopoietic cell transplant (HCT) for patients with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) acute myeloid leukemia (AML). Although promising outcomes have been reported for...